Biomarkers Can PREDICT Cutaneous Leishmaniasis Treatment Failure EARLY

Title
"Predictive Biomarkers in Cutaneous Leishmaniasis: Unlocking Early Treatment Failure – Health Headliner Podcast With Michael & Amber."- 🔬 - E210

Podcast Description
Join hosts Michael and Amber on this episode of the Health Headliner Podcast as they discuss breakthrough research on cutaneous leishmaniasis (CL) treatment. Discover how a sustained type I interferon response in innate immune cells is linked to treatment failure with meglumine antimoniate. Learn about the innovative composite biosignature—derived from 11 gene expression profiles in monocytes, neutrophils, and eosinophils—that can predict which patients are unlikely to respond to standard therapy. This episode explores the potential of these biomarkers to guide personalized treatment strategies and host-directed therapies, offering hope for improved outcomes in endemic regions. Tune in to understand how these findings can transform patient management in resource-limited settings and shape the future of CL therapy.

Hashtags:
#Cutaneous
#Leishmaniasis
#Biomarkers
#TreatmentFailure
#Interferon
#Immunity
#GeneExpression
#Transcriptomics
#HostTherapy
#HealthPodcast

Keywords:
CL
Bio
Gene
IFN
Immune
Host
Therapy
Predict
Trans
Health
Follow us on Social Media:
For more updates, follow us on social media and subscribe to our channel! https://www.youtube.com/channel/UCQvJCdrUxl-AkVmGr49c1aA
https://www.tiktok.com/@toudou_digital
https://www.facebook.com/profile.php?id=61551746523905
Reference:
María Adelaida Gómez et al,
Innate biosignature of treatment failure in human cutaneous leishmaniasis,
Nature Communications (2025).
DOI: 10.1038/s41467-025-58330-3
Contact us:
For comments, suggestions, or to reach out directly, please contact: anthonytoudou@gmail.com

Видео Biomarkers Can PREDICT Cutaneous Leishmaniasis Treatment Failure EARLY канала Health Headliner Podcast